Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-09-27

Clinical Trial Update: A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating certolizumab pegol added to methotrexate for rheumatoid arthritis, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Certolizumab pegol (certolizumab pegol)
  • METHOTREXATE (METHOTREXATE)

Snippet

Sponsor: Korea Otsuka Pharmaceutical Co., Ltd. | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2012-09-27